Neural Therapeutics Inc. · CSE:NURL
Neural Therapeutics — Investor Presentation (February 2024)
30 slides from Neural Therapeutics's investor presentation, February 2024
Slide 1: Neural Therapeutics Inc. Corporate Presentation
Neural Therapeutics Inc. Corporate Presentation February 2024
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements CONFIDENTIAL INFORMATION NOT AN OFFER This presentation (the “Presentation"), inclusive of all materials and information provided herewith This Presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any s
Slide 3: Disclaimer and Forward-Looking Statements (cont.)
Disclaimer and Forward-Looking Statements (cont.) FORWARD LOOKING STATEMENT AND RISK FACTORS Certain statements contained in this Presentation relate to the historical experience of our founders, management team This Presentation includes certain “forward-looking information” and “forward-looking st
Slide 4: 2024 Will Be a Breakthrough Year for Psychedelic Investments
2024 Will Be a Breakthrough Year for Psychedelic Investments • May 2nd the American Medical Association announced new billing codes for psychedelic therapies upon regulatory approval • June 23rd FDA Issues First Draft Guidance on Clinical Trials with Psychedelic Drugs • July 1st Australia became the
Slide 5: Executive Overview
Executive Overview • Neural Therapeutics Inc. is a life sciences company focused on the research and development of compounds from psychoactive plants. • Our first target is mescaline from the San Pedro cactus (Echinopsis pachanoi or Trichocereus pachanoi) • Peer-reviewed and historical scientific l
Slide 6: About Psychedelic Cacti
About Psychedelic Cacti Indigenous/Native populations have used Peyote and San Pedro as botanical medicines for millennia Contains the highest concentration of Mescaline – around 3 to 6% of Despite the lower mescaline the dried weight concentration at around 1 - 4.5%, San Pedro Cactus the larger mas
Slide 7: Efficacy: Mescaline a Potential Game Changing Therapeutic
Efficacy: Mescaline a Potential Game Changing Therapeutic Effective in Treating Mental Health Conditions • Mescaline shows promise as a treatment option for challenging mental health conditions. Conditions Addressed • Effective in managing complex mental ailments. Evidence of Treating Comorbidities
Slide 8: Advantages: Plant-Derived Mescaline
Advantages: Plant-Derived Mescaline Mescaline Isolation and Purification ❖ Precedent: Epidiolex/EpidyolexTM, purified cannabidiol derived from plant and manufactured into an FDA- and EMA- approved oral solution for the treatment of seizures associated with certain forms of epilepsy Mescaline PLUS Ot
Slide 9: Market Stats - Pharmaceutical
Market Stats - Pharmaceutical $70+ billion total market Institutional Market Momentum ADHD: $29.6 Billion Smoking Cessation: $23.4 Billion Depression*: $12.1 Billion Substance Abuse Treatment*: $16.5 Billion • Veterans of War & Heroic Hearts Project: non-profits that connect military veterans strugg
Slide 10: Mescaline: Neural Therapeutics Advantage
Mescaline: Neural Therapeutics Advantage A holistic approach to the plant Historical Use: Mescaline from cacti has been used for at least 5,700 years(1) throughout North America Safety: Mescaline requires larger doses vs. other psychedelics to achieve hallucinogenic effects Use in Therapy: Mescaline
Slide 11: R&D Targeted Near-Term Objectives – Pharmaceutical and Nutraceutical
R&D Targeted Near-Term Objectives – Pharmaceutical and Nutraceutical Supply Chain: Expect to have cGMP supply chain agreement complying with US FDA standards by Q1 Partners: Expect CROs selection by year end, to conduct pre-clinical and clinical studies according to ICH, GLP and GCP guidelines (for
Slide 12: Research & Development Pathway
Research & Development Pathway Pharmaceutical Development • Pre-Clinical Studies: Create a formulation(s) that can be tested in IND- enabling studies Supply Chain Permits and Studies • Clinical Studies: Conduct Phase I – III clinical trials (after regulatory approval) $70+ Optimizing Extraction Gov.
Slide 13: Past Milestones
Past Milestones Company Acquisition by CRO engaged for Comprehensive Engaged Additional CROs Peru is selected as the Identify New Management Successfully Formed. Nutritional High initial North Mescaline Research regulatory and legal advisors location of focus of the sources of Team, Board of closed
Slide 14: Recent Developments
Recent Developments Legal Spin-out Peruvian federal National Partner for Patent application Cactus Cultivator 2nd Patent Completed – permit genetic SERFOR and Service submitted - a novel Cultivation Supply Chain application May 23rd study of flora and Contract established method of Experiment Agreem
Slide 15: Partners: Supply Chain and Strategic Partners
Partners: Supply Chain and Strategic Partners Supply Chain: Established a robust, international supply chain on 3 continents Cultivation Locations: USA, Peru, Spain, Australia Sustainability: A collection of large suppliers forming the largest access to cultivated San Pedro globally Chemistry: Extra
Slide 16: Notable Milestones and Objectives
Notable Milestones and Objectives 2022 2023 2024+ ➢ IP - Commenced documentation of patentable ➢ Create a rapid method for determining ➢ IP-Extraction and formulations defined extraction technologies/procedures Mescaline quantities in plants (IP) ➢ Identify and engage an CMO/CMC partner ➢ Engaged re
Slide 17: Share Structure
Share Structure Number Common Shares Currently Issued and Outstanding(1) 65,771,692 Financing Warrants ($0.05 - $1.00 for 2 years) 7,546,660 RSUs and Options1 4,989,833 Broker Warrants ($0.05-$0.075 for 2 years) 1,016,164 Fully-Diluted Shares Issued and Outstanding 79,324,349 1 – Each of Neural Stoc
Slide 18: Scientific & Impact Advisory Committee
Scientific & Impact Advisory Committee Professor David Nutt, MD – David Nutt is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Imperial College London. He was previously President of the European Brain Council, British Association of Psy
Slide 19: Leadership Team
Leadership Team Ian Campbell, MSc – Chief Executive Officer and Director – Mr. Campbell is an executive leader who has an international reputation for building effective teams, managing operations and product commercialization. He has managed multinational entities residing in the US, Canada as well
Slide 20: Contact Information
Contact Information Ian Campbell, CEO Neural Therapeutics Inc. C: 226-218-2255 E: [email protected] 77 King Street West, Suite 2905 Toronto, ON M5K 1H1 22
Slide 21: Appendix
Appendix 23
Slide 22: Sources – Market Statistics
Sources – Market Statistics Pharmaceutical • ADHD: ADHD Therapeutics Market Size, Trends & Growth | 2021 to 2026 (marketdataforecast.com) • Anti-addiction: Addiction Treatment Market Size is Projected to Reach US$ 11 Billion by 2027 – The Market Publicist • Anxiety: Anxiety Disorders and Depression
Slide 23: Additional Sources
Additional Sources Market Statistics – Nutraceutical • Dietary Fat Uptake Reduction: https://pubmed.ncbi.nlm.nih.gov/25067985 • Diabetic Control Benefits of Cacti: Antidiabetic Effect of Fresh Nopal (Opuntia ficus-indica) in Low-Dose Streptozotocin-Induced Diabetic Rats Fed a High-Fat Diet (hindawi.
Slide 24: History of Mescaline
History of Mescaline Mescaline has been widely used throughout our history Mescaline is found in the fast- Dr. John Raleigh Briggs wrote German pharmacologist and physicist Failure of Mescaline to solve the growing San Pedro cactus and the about his experience after eating Arthur Heffter isolated th
Slide 25: Scientific Leadership: Neural Therapeutics – Contributes
Scientific Leadership: Neural Therapeutics – Contributes Vamvakopoulou IA, Narine KAD, Campbell I, Dyck JRB, Nutt DJ. Mescaline: The forgotten psychedelic. Neuropharmacology. 2022 Oct 14:109294. doi: 10.1016/j.neuropharm.2022.109294. Epub ahead of print. PMID: 36252614. 27
Slide 26: Neural Therapeutics Philosophy
Neural Therapeutics Philosophy Why we are focusing on mescaline from natural sources, in particular the San Pedro cactus? Mescaline is Different Honoring Ethnobotanical Use ❖ Mescaline has a unique receptor drug affinity and response than ❖ Thousands of years of historical experience is an invaluabl
Slide 27: Mescaline vs. Other Psychedelics
Mescaline vs. Other Psychedelics Typical Psychedelic Molecular Duration of Hallucinogenic Potential Therapeutic Uses Onset of Effects Substance Structure Effects Dose Addiction (e.g., alcohol), Anxiety LSD 0.05 - 0.2 mg 30 - 40 min 8 - 12h associated with terminal illness Addiction (tobacco, alcohol
Slide 28: Market Stats - Nutraceutical
Market Stats - Nutraceutical $175+ billion total market ❖ Benefits: Cacti are high in fiber, antioxidants carotenoids, vitamins Dietary $140 Billion Weight Loss Supplements: $24 Billion and a source of amino + fatty acids Supplements: ❖ Clinical Data: Cacti fiber scavenges dietary fat and reduce obe
Slide 29: Nutraceutical Market Strategy
Nutraceutical Market Strategy The nutraceutical strategy will focus on monetizing the non-mescaline portion of the cactus. Mescaline is not equally distributed throughout San Pedro. It resides mainly in the outer surfaces. Our focus will be to efficiently extract mescaline and other medically benefi
Slide 30: R&D Targeted Deliverables Objectives - Nutraceutical
R&D Targeted Deliverables Objectives - Nutraceutical Focus on extracting benefit from all parts of the cactus plant. ❖ Raw Material: The residual San Pedro solids and extracts separated from mescaline are the raw materials – determine the composition of the parts that have potential therapeutic bene
Neural Therapeutics — Investor Presentation (February 2024) on 6ix